UC AKTPRO 25 LLY/ DE000HV4XLY6 /
2024-08-09 6:11:00 PM | Chg.+1.090 | Bid7:59:37 PM | Ask- | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
99.810EUR | +1.10% | 99.780 Bid Size: 50,000 |
- Ask Size: - |
Eli Lilly and Co | 734.97 USD | 2025-05-07 | Call |
GlobeNewswire
07-01
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studyi...
GlobeNewswire
06-28
Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combin...
GlobeNewswire
06-21
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
GlobeNewswire
06-11
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D ...
GlobeNewswire
06-10
Sermonix Pharmaceuticals Announces Breast Cancer Research Publication of Paper Examining Lasofoxifen...
GlobeNewswire
06-06
Sermonix Pharmaceuticals Announces Chinese Approval of Investigational New Drug Application for Laso...
GlobeNewswire
05-30
Sermonix Pharmaceuticals to Present Poster on ELAINE-3 Trial in Progress at ASCO 2024
GlobeNewswire
05-30
Anaqua Annual User Experience Conference to Feature Keynotes from Microsoft, SAP, USPTO, and More
GlobeNewswire
05-24
Gov. Holcomb Joins Lilly to Announce Additional $5.3 Billion Investment at LEAP District
GlobeNewswire
05-16
BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED ...